Association between two genetic polymorphisms of the renin-angiotensin-aldosterone system and diabetic nephropathy: a meta-analysis

2011 ◽  
Vol 39 (2) ◽  
pp. 1293-1303 ◽  
Author(s):  
Wei Ding ◽  
Furu Wang ◽  
Qiaoqiao Fang ◽  
Minmin Zhang ◽  
Jing Chen ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Genetic Polymorphisms ◽  
Meta Analysis ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin

Renin–Angiotensin–Aldosterone System Gene Polymorphisms and Type 2 Diabetic Nephropathy in Asian Populations: An Updated Meta-analysis

2019 ◽  
Vol 15 (4) ◽  
pp. 263-276 ◽  
Author(s):  
Norfazilah Ahmad ◽  
Rahman Jamal ◽  
Shamsul Azhar Shah ◽  
Abdul Halim Abdul Gafor ◽  
Nor Azian Abdul Murad
Keyword(s):  
Diabetic Nephropathy ◽  
Meta Analysis ◽  
Recessive Model ◽  
Reference List ◽  
Angiotensin Ii Receptor ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin ◽  
Subgroup Differences ◽  
Asian Populations

Background: The association of polymorphisms in the renin-angiotensin-aldosterone system candidate genes, namely Angiotensin-Converting Enzyme (ACE) Insertion/Deletion (I/D), Angiotensinogen (AGT) M235T and Angiotensin II Receptor Type 1 (AGTR1) A1166C with Diabetic Nephropathy (DN) has been studied for decades. Objective: This meta-analysis aimed to assess the updated pooled effects of these polymorphisms with DN among Asian populations with type 2 diabetes mellitus. Methods: The PubMed electronic database was searched without duration filter until August 2017 and the reference list of eligible studies was screened. The association of each polymorphism with DN was examined using odds ratio and its 95% confidence interval based on dominant, recessive and allele models. Subgroup analyses were conducted based on region, DN definition and DM duration. Results: In the main analysis, the ACE I/D (all models) and AGTR1 A1166C (dominant model) showed a significant association with DN. The main analysis of the AGT M235T polymorphism did not yield significant findings. There were significant subgroup differences and indication of significantly higher odds for DN in terms of DM duration (≥10 years) for ACE I/D (all models), AGT M235T (recessive and allele models) and AGTR1 A1166C (recessive model). Significant subgroup differences were also observed for DN definition (advanced DN group) and region (South Asia) for AGTR1 A1166C (recessive model). Conclusion: In the Asian populations, ACE I/D and AGTR1 A1166C may contribute to DN susceptibility in patients with T2DM by different genetic models. However, the role of AGT M235T needs to be further evaluated.

scholarly journals META-ANALYSIS OF SAFETY AND EFFICACY OF RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITORS IN COVID-19 POPULATION

2021 ◽  
Vol 77 (18) ◽  
pp. 3158
Author(s):  
Yasar Sattar ◽  
Pradeeksha Mukuntharaj ◽  
Hassan Attique ◽  
Waqas Ullah ◽  
Muhammad Khawar Sana ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Renin Angiotensin Aldosterone System ◽  
Safety And Efficacy ◽  
Renin Angiotensin

Renin-angiotensin-aldosterone system blockers for diabetic nephropathy

Vrach ◽  
2021 ◽  
Vol 32 (10) ◽  
pp. 16-24
Author(s):  
A. Bagriy ◽  
M. Khomenko ◽  
E. Mikhailichenko
Keyword(s):  
Diabetic Nephropathy ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin

scholarly journals Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy

2020 ◽  
Vol 21 (2) ◽  
pp. 147032032091958
Author(s):  
Weidong Wang ◽  
Wei Qu ◽  
Dan Sun ◽  
Xiaodan Liu
Keyword(s):  
Older People ◽  
Sample Size ◽  
Meta Analysis ◽  
Control Group ◽  
Inclusion Criteria ◽  
Contrast Induced Nephropathy ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin ◽  
Increased Risk ◽  
Larger Sample

Background: The purpose of this study was to systematically evaluate the effect of renin–angiotensin–aldosterone system blockers on the incidence of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous coronary intervention. Methods: A systematic literature search of several databases was conducted to identify studies that met the inclusion criteria. A total of 12 studies with 14 trials that performed studies on a total of 4864 patients (2484 treated with renin–angiotensin–aldosterone system blockers and 2380 in the control group) were included. The primary endpoint was the overall incidence of contrast-induced nephropathy. Analyses were performed with STATA version 12.0. Results: The overall contrast-induced nephropathy incidence in renin–angiotensin–aldosterone system blocker and control groups was 10.43% and 6.81%, respectively. The pooled relative risk of contrast-induced nephropathy incidence was 1.22 (95% confidence interval: 0.81–1.84) in the renin–angiotensin–aldosterone system blocker group. An increased risk of developing contrast-induced nephropathy in the renin–angiotensin–aldosterone system blocker group was observed among older people, non-Asians, chronic users, and studies with larger sample size, and the pooled RRs and 95% confidence intervals were 2.02 (1.21–3.36), 2.30 (1.41–3.76), 1.69 (1.10–2.59) and 1.83 (1.28–2.63), respectively. Conclusions: Intervention with renin–angiotensin–aldosterone system blockers was associated with an increased risk of contrast-induced nephropathy among non-Asians, chronic users, older people, and studies with larger sample size. Large clinical trials with strict inclusion criteria are needed to confirm our results and to evaluate the effect further.

Sign in / Sign up

Export Citation Format

Share Document